Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex.
Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pa.
J Thorac Cardiovasc Surg. 2018 Jul;156(1):406-413.e3. doi: 10.1016/j.jtcvs.2018.02.093. Epub 2018 Mar 12.
Endoscopic mucosal resection (EMR) is a diagnostic and potentially therapeutic option for patients with submucosal esophageal adenocarcinoma. However, there are significant concerns regarding the risk of lymph node metastasis. Our purpose was to construct a comparative effectiveness analysis comparing recurrence patterns after therapeutic EMR or esophagectomy.
Patients who underwent therapeutic EMR or esophagectomy from 2007 to 2015 with pathologically staged submucosal adenocarcinoma were identified from a departmental database. Cancer-related outcomes were compared among an unmatched as well as a propensity matched cohort. Risk stratification was also used to compare results among those with a low, medium, or high risk of nodal metastasis.
Seventy-two patients met criteria for analysis, among whom 23 underwent therapeutic EMR with esophageal preservation and 49 underwent esophagectomy. Median follow-up was 43 months. Patients who underwent esophagectomy had larger, deeper tumors. Esophageal preservation was associated with an increased risk of local recurrence (P = .01), but not distant recurrence (P = .44). After propensity matching, there continued to be no difference in distant recurrence rate (P = .66). In a risk-stratified analysis, low-risk patients showed no recurrences or cancer-related deaths, however, high-risk patients showed a trend toward increased distant recurrence after therapeutic EMR.
Esophageal preservation after therapeutic EMR was associated with an increased risk of local recurrence. Among low-risk patients, either strategy resulted in excellent cancer control. However, among high-risk patients, esophageal preservation showed a trend toward increased distant failure. These findings should prompt further investigation to determine optimal treatment for patients with submucosal esophageal adenocarcinoma.
内镜黏膜下剥离术(EMR)是治疗黏膜下食管腺癌患者的一种诊断和潜在的治疗选择。然而,对于淋巴结转移的风险存在重大担忧。我们的目的是构建一项对比分析,比较治疗性 EMR 或食管切除术治疗后的复发模式。
从一个科室数据库中确定了 2007 年至 2015 年间接受治疗性 EMR 或食管切除术且病理分期为黏膜下腺癌的患者。比较未匹配和倾向匹配队列中癌症相关结局。风险分层也用于比较低、中、高淋巴结转移风险患者的结果。
72 名患者符合分析标准,其中 23 名患者接受了保留食管的治疗性 EMR,49 名患者接受了食管切除术。中位随访时间为 43 个月。接受食管切除术的患者肿瘤更大、更深。食管保留与局部复发风险增加相关(P=0.01),但与远处复发无关(P=0.44)。在倾向匹配后,远处复发率仍无差异(P=0.66)。在风险分层分析中,低危患者无复发或癌症相关死亡,但高危患者经治疗性 EMR 后远处复发的趋势增加。
治疗性 EMR 后食管保留与局部复发风险增加相关。在低危患者中,两种策略都能获得极好的癌症控制。然而,在高危患者中,食管保留与远处失败的趋势增加相关。这些发现应促使进一步研究,以确定治疗黏膜下食管腺癌患者的最佳方法。